IQ-AI Ltd

("IQ-AI" or the "Company")

Major East Coast Health System Chooses IB Nimble for Their Brain Metastases Program of Excellence

Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), today announces that a leading cancer centre located on the eastern seaboard has subscribed to IB Nimble to optimize the care for patients with metastatic brain cancer. IB Nimble is a handheld app, available on iOS and Android devices and a web-based desktop version, that enables secure, remote, and asynchronous discussions amongst multidisciplinary specialists.

Brain metastases occur when cancer cells spread to the brain from their original site. This is common with breast, lung, and skin (melanoma) cancers. Metastases are the most common type of brain cancer, and their prevalence is increasing. This is due in part to the improved treatments for those other cancers. As patients with these other cancers live longer, it is more likely those cancer cells will eventually migrate to the brain.  

The modern care of patients diagnosed with brain metastases requires expert input from specialists in medical oncology, radiation oncology, neuro-oncology, neurosurgery, and palliative care. This input is typically obtained during weekly meetings or "tumor boards". Depending on when a patient is admitted, they may need to wait multiple days until the tumor board meets before a treatment plan can be developed.

Treatment decisions require timely discussions to provide optimal personalized care. IB Nimble is integral to this effort as it facilitates real-time discussion and collaboration amongst all the multidisciplinary specialists. The mobile app will be used to improve the quality of care by, for example, improving patient-reported outcomes, avoiding unnecessary hospital admissions, and decreasing the length of hospital stays.

"The potential for multi-site collaboration is now literally in our hands with IB Nimble," said Dr. Joe Bovi, MD, one of the inventors of IB Nimble. "We look forward to working very closely with this health care centre," Dr. Bovi added.

"The product roadmap for IB Nimble is clear. By the end of 2024, our development team will have completed significant enhancements to the software architecture, including the addition of a highly requested feature - viewing medical images," said Tim Dondlinger, COO of IB. "In advance of that, we are already working on our sales pipeline," added Mr. Dondlinger.

--ENDS-

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com. Follow IB on Twitter, @IQAI_IB.